Effects of coronary revascularization with or without cardiopulmonary bypass on plasma levels of asymmetric dimethylarginine

Coronary Artery Disease

Volumn 22, Issue 4, 2011, Pages 245-252

  Cziráki, Attila ^a   Ajtay, Zénó ^a   Németh, Ádám ^a   Lenkey, Zsófia ^a   Sulyok, Endre ^b   Szabados, Sándor ^a   Alotti, Nasri ^c   Martens Lobenhoffer, Jens ^d   Szabó, Csaba ^e   Bode Böger, Stefanie M ^d  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Faculty of Health Sciences   (Hungary)

^c Zala County Hospital   (Hungary)

^d UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Asymmetric dimethylarginine; coronary heart disease; revascularization

Indexed keywords

6 N,N' DIMETHYLARGININE; ARGININE; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY SINUS; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; OFF PUMP CORONARY SURGERY; PATIENT MONITORING; PERIPHERAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ARGININE; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; REPERFUSION INJURY; TANDEM MASS SPECTROMETRY;

EID: 79955582032     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283441d5c     Document Type: Article

References (34)

1. Jerrold H, Kenicki A. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 59:715-720.
2. Akila, D'souza B, Vishwanath P, D'souza V. Oxidative injury and antioxidants in coronary artery bypass graft surgery: Off-pump CABG significantly reduces oxidative stress. Clin Chim Acta 2006; 375:147-152.
3. Raja SG, Berg GA. Impact of off-pump coronary artery bypass surgery on systemic inflammation: Current best available evidence. J Card Surg 2007; 22:445-455. (Pubitemid 47353029)
4. Biglioli P, Cannata A, Alamanni F, Maliato M, Porqueddu M, Zanobini M, et al. Biological effects of off-pump vs. on-pump coronary artery surgery: Focus on inflammation, hemostasis and oxidative stress. Eur J Cardiothorac Surg 2003; 24:260-269. (Pubitemid 36952192)
5. Ascione R, Lloyd CT, Underwood MJ, Lotto AA, Pitsis AA, Angelini GD. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 2000; 69:1198-1204. (Pubitemid 30259386)
6. Matata BM, Sosnowski AW, Galinanes M. Off-pump bypass graft operation significantly reduces oxidative stress and inflammation. Ann Thorac Surg 2000; 69:785-791. (Pubitemid 30184698)
7. Van Snick J. Interleukin-6: An overview. Ann Rev Immunol 1990; 8: 253-278. (Pubitemid 20135628)
8. Gerritsen WBM, Van Boven WJP, Driessen AHG, Haas FJLM, Aarts LPHJ. Off-pump versus on-pump coronary artery bypass grafting: Oxidative stress and renal function. Eur J Cardiothorac Surg 2001; 20:923-929. (Pubitemid 33042392)
9. Meldrum DR, Cleveland JC Jr, Cain BS, Meng X, Harken AH. Increased myocardial tumor necrosis factor-alpha in crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 1998; 65:439-443. (Pubitemid 28083341)
10. Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: Insights from prospective clinical trials. Vasc Med 2005; 10: S19-S25. (Pubitemid 43137264)
11. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG, NG-dimethylarginine dimethylamino-hydrolase, from rat kidney. J Biol Chem 1989; 264:10205-10209. (Pubitemid 19159295)
12. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: Role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92:226-233. (Pubitemid 36254279)
13. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-2012. (Pubitemid 24015045)
14. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
15. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99-105. (Pubitemid 30616904)
16. Cable DG, Celotto AC, Evora PR, Schaff HV. Asymmetric dimethylargnine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med Sci Monit 2009; 15:248-253.
17. Hasegawa K, Wakino S, Tatematsu S, Yoshioka K, Homma K, Sugano N, et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase. Circ Res 2007; 101:e2-e10. (Pubitemid 47196589)
18. Toth J, Racz A, Kaminski PM, Wolin MS, Bagi Z, Koller A. Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone. Hypertension 2007; 49:563-568.
19. Hori T, Matsubara T, Ishibashi T, Ozaki K, Tsuchida K, Mezaki T, et al. Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina. Circ J 2003; 67:305-311. (Pubitemid 36417597)
20. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the Athero Gene Study. Circ Res 2005; 97:E53-E59.
21. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127-2128. (Pubitemid 34094905)
22. Ajtay Z, Scalera F, Cziraki A, Horvá th I, Papp L, Sulyok E, et al. Stent placement is patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA. Int J Mol Med 2009; 23:651-657.
23. Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography- electrospray tandem mass spectrometry. Clin Chem 2006; 42:448-493.
24. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetric dimethylarginine and adverse cardiovascular events after percutaneous coronary interventions. Eur Heart J 2003; 24:1912-1919.
25. Scalera F, Martens-Lobenhoffer J, Tager M, Bukowska A, Lendeckel U, Bode-Böger SM. Effects of L-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging. Biochem Biophys Res Commun 2006; 345:1075-1082. (Pubitemid 43776488)
26. Osanai T, Saitoh M, Sasak S, Tomita H, Matsugana T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42:985-990. (Pubitemid 37413742)
27. Bode-Böger SM, Scalera F, Ignarro LJ. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmac Ther 2007; 114:295-306. (Pubitemid 46843253)
28. Walker HA, Mc Ging E, Fisher I, Böger RH, Bode-Böger SM, Jackson G, et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina. J Am Coll Card 2001; 38:499-505.
29. Borland JA, Chester AH, Yacoub MH. The renin-angiotensin system in bypass graft surgery. Curr Op Cardiol 2000; 15:371-377.
30. Borland JA, Chester AH, Crabbe S, Parkerson JB, Catravas JD, Yacoub MH. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac Cardiovasc Surg 1998; 116: 206-212. (Pubitemid 28367085)
31. Mollnau H,Wendt M, Szocs K, Lasségue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90:E58-E65.
32. Napoli C, Sica V, de Nigris F, Pingalosa O, Condorelli M, Ignarro LJ. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148:e5.
33. Sajionmaa O, Nyman T, Fyhrquist F. Downregulation of angiotensinconverting enzyme by tumor necrosis factor-alpha and interleukin-1 beta in cultured human endothelial cells. J Vasc Res 2001; 38:370-378. (Pubitemid 32678952)
34. Veresh Z, Racz A, Lotz G, Koller Á ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension 2008; 52:960-966.